

**BIOLIDICS LIMITED**  
(Company Registration Number: 200913076M)

---

**APPOINTMENT OF CK LIFE SCIENCES INTERNATIONAL INC. AS A NON-EXCLUSIVE  
DISTRIBUTOR FOR BIOLIDICS' NOVEL CORONAVIRUS 2019 RAPID TEST KITS**

---

The board of directors (the "**Board**") of Biolidics Limited (the "**Company**") and together with its subsidiaries, the "**Group**") is pleased to announce that the Company had on 14 April 2020, entered into a distribution agreement (the "**Agreement**") with CK Life Sciences Int'l., Inc. ("**CKLSII**"). Under the terms of the Agreement, CKLSII is appointed as a non-exclusive distributor of the Company's rapid test kits for the Novel Coronavirus 2019, in the Hong Kong Special Administrative Region for a duration of three years from the date of the Agreement.

CKLSII is a wholly-owned subsidiary of Hong Kong-listed CK Life Sciences Int'l., (Holdings) Inc ("**CK Life Sciences**"), which is a member of the CK Hutchison Group. CK Life Sciences is engaged in the business of research and development, manufacturing, commercialisation, marketing, sale of, and investment in, products and assets which fall into three core categories - nutraceuticals, pharmaceuticals, and agriculture-related.

As at the date of this announcement, the Company is unable to ascertain the financial impact of the Agreement on the Group for the financial year ending 31 December 2020.

Shareholders and other investors are reminded to exercise caution when dealing in the securities of the Company and should consult their stockbrokers, bank managers, solicitors, accountants or other professional advisers if they are in doubt about the actions that they should take.

Save for their respective shareholdings in the Company (if any), the Company is not aware of any of its Directors or substantial shareholders having any interest, direct or indirect in the Agreement.

**BY ORDER OF THE BOARD**

**Yee Pinh Jeremy**  
**Non-Executive Non-Independent Chairman**  
**15 April 2020**

*This announcement has been prepared by Biolidics Limited (the "Company") and has been reviewed by the Company's sponsor, United Overseas Bank Limited (the "Sponsor"), for compliance with Rules 226(2)(b) and 753(2) of the Singapore Exchange Securities Trading Limited (the "SGX-ST") Listing Manual Section B: Rules of Catalyst. This announcement has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.*

*The contact person for the Sponsor is Mr Chia Beng Kwan, Senior Director, Equity Capital Markets, who can be contacted at 80 Raffles Place, #03-03 UOB Plaza 1, Singapore 048624, telephone: +65 6533 9898.*